Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion

Bloomberg
20 May

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores multinational drugmakers’ growing enthusiasm for Chinese biotech innovation.

The deal grants Pfizer rights to develop and commercialize a drug from Shenyang-based 3SBio Inc. currently in clinical testing for multiple tumor types, according to a press release. In addition to the upfront payment — which sets a new record for China licensing deals — 3SBio is eligible for up to $4.8 billion in downstream fees if the drug hits all milestones.

Shares of 3SBio jumped as much as 38.28% in Hong Kong.

The deal lifted health-care peers on Tuesday, including ApicHope Pharmaceutical Group Co. and Zhejiang Huahai Pharmaceutical Co., whose shares rose by the 20% and 10% onshore daily limits, respectively.

A health-care subgauge was the top performer among Hang Seng Composite Index, jumping as much as 3.8%. CSPC Pharmaceutical Group Ltd. and Innovent Biologics Inc. gained as much as 9.6% and 8.9%, respectively, in Hong Kong.

Betting on China

The pact with Pfizer was a record outbound deal for a Chinese biotech firm, according to Rebecca Liang, a pharmaceutical and biotechnology senior analyst at Bernstein.

“From the market reactions we see investors take this as a testament to the increasingly innovative quality of the sector as a whole,” she said.

US pharmaceutical giant Pfizer will also make a $100 million equity investment in Hong Kong-listed 3SBio, which sells a range of medicines in China for cancer, autoimmune diseases, kidney conditions, skin disorders and more.

Many of Pfizer’s peers have bet on China-originated drugs to refill their pipelines over the past year. Novo Nordisk A/S and Merck & Co. Inc. both shelled out $200 million upfront in recent months for an obesity drug and a heart medicine, respectively.

With this new deal, Pfizer is joining a small club of challengers going after Merck’s Keytruda, the world’s top-selling medicine. 3SBio’s drug works in the same way as a therapy from China’s Akeso Inc. that outperformed Keytruda in one trial. Notably, Merck also picked up a similar drug from Chinese biotech LaNova Medicines.

3SBio plans to start the first late-stage study for the drug in China this year. While Pfizer did not outline its own clinical plans, it said in a statement that it will manufacture the drug in the US.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10